Big data has been one of the hottest buzzwords across all industries over the last few years and that doesn't seem to be changing anytime soon. Generally speaking, big data refers to large data sets that are to be analyzed to reveal patterns, trends, and associations that relate human behavior/interactions.
Pharma and biotech companies are not the first to this space and there is a lot that can be learned from other industries and those who have gone before, especially in regulated industries. William Tannenbaum, Co-Head of Technology Transactions Practice at Arent Fox LLP sat down with us to explore many of the major issues surrounding data ownership, best practices, privacy, and how the pharma/biotech industry can learn from other companies who have already been through this data revolution.
Watch the full interview with William Tannenbaum above to hear his perspective on these key issues and how they relate to our industry;
- What can companies in pharma/biotech learn from companies in other industries regarding data practices?
- Regarding data practices, what differentiates best practices from best-of-breed?
- What are the primary issues around data ownership that companies need to consider? How should companies address these issues?
- Privacy is obviously another key consideration. What are the issues here around privacy and what do companies need to think about?